These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 19622904)

  • 1. Emerging pharmacologic therapies for wet age-related macular degeneration.
    Ni Z; Hui P
    Ophthalmologica; 2009; 223(6):401-10. PubMed ID: 19622904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
    Ferrara N; Damico L; Shams N; Lowman H; Kim R
    Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-angiogenic therapy of exudative age-related macular degeneration: current progress and emerging concepts.
    Noël A; Jost M; Lambert V; Lecomte J; Rakic JM
    Trends Mol Med; 2007 Aug; 13(8):345-52. PubMed ID: 17644433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Intravitreal anti-VEGF injections improve the visual prognosis of wet age related macular degeneration].
    Ambresin A; Mantel I
    Rev Med Suisse; 2007 Jan; 3(94):137-41. PubMed ID: 17354539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging therapies for the treatment of neovascular age related macular degeneration.
    Yuan A; Kaiser PK
    Semin Ophthalmol; 2011 May; 26(3):149-55. PubMed ID: 21609228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging therapies for the treatment of wet age-related macular degeneration--VEGF Trap-Eye.
    Rejdak R; Szkaradek M; Grieb P; Jünemann AG
    Klin Oczna; 2011; 113(10-12):376-8. PubMed ID: 22384659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy for age-related macular degeneration.
    Patel S
    Retina; 2009 Jun; 29(6 Suppl):S45-8. PubMed ID: 19553801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age-related macular degeneration.
    Brucker AJ
    Retina; 2009 Jun; 29(6 Suppl):S2-4. PubMed ID: 19553791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacological therapy for age-related macular degeneration. Current developments and perspectives].
    Holz FG; Miller DW
    Ophthalmologe; 2003 Feb; 100(2):97-103. PubMed ID: 12589452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neovascular age-related macular degeneration: potential therapies.
    Chappelow AV; Kaiser PK
    Drugs; 2008; 68(8):1029-36. PubMed ID: 18484796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of neovascular age-related macular degeneration with Ranibizumab/Lucentis].
    Michels S; Rosenfeld PJ
    Klin Monbl Augenheilkd; 2005 Jun; 222(6):480-4. PubMed ID: 15973626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration.
    Tuñón J; Ruiz-Moreno JM; Martín-Ventura JL; Blanco-Colio LM; Lorenzo O; Egido J
    Surv Ophthalmol; 2009; 54(3):339-48. PubMed ID: 19422962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Status of therapies in development for the treatment of age-related macular degeneration.
    Hunt DW; Margaron P
    IDrugs; 2003 May; 6(5):464-9. PubMed ID: 12789601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging therapies for neovascular age-related macular degeneration: drugs in the pipeline.
    Kaiser PK
    Ophthalmology; 2013 May; 120(5 Suppl):S11-5. PubMed ID: 23642781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic Treatment of Wet Type Age-related Macular Degeneration; Current and Evolving Therapies.
    Shams Najafabadi H; Daftarian N; Ahmadieh H; Soheili ZS
    Arch Iran Med; 2017 Aug; 20(8):525-537. PubMed ID: 28846017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic approaches to age-related macular degeneration today.
    Bressler NM
    Ophthalmology; 2009 Oct; 116(10 Suppl):S15-23. PubMed ID: 19800535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ranibizumab for treatment of exudative age-related macular degeneration--own experience].
    Wykrota H; Gierek-Lapińska A; Trzciakowski K; Gajdzik-Gajdecka U
    Klin Oczna; 2007; 109(10-12):402-9. PubMed ID: 18488382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs in Phase II clinical trials for the treatment of age-related macular degeneration.
    Tolentino MJ; Dennrick A; John E; Tolentino MS
    Expert Opin Investig Drugs; 2015 Feb; 24(2):183-99. PubMed ID: 25243494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.
    Ciulla TA; Rosenfeld PJ
    Curr Opin Ophthalmol; 2009 May; 20(3):166-74. PubMed ID: 19381089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.